Premature sebaceous gland hyperplasia: Successful treatment with isotretinoin

Burton, Claude S.; Sawchuk, William S.

doi:10.1016/s0190-9622(85)80013-x

Cited by 33 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other conditions accompanied by a hyperplasia of the scboglandular unit are premature, mature and senile sebaceous gland hyperplasia whose occurrence can be in part familial or spontaneous. Here isotretinoin likewise is very effective, some times at very low doses [29][30][31][32]. In addition, there are increasing indications that iso tretinoin may also exert an influence on the androgen receptor [33,34], From the group of acne-related disor ders, gram-negative folliculitis and severe rosacea have become absolute indications.…”

Section: Isotretinoinmentioning

confidence: 99%

New Indications and New Retinoids

Gollnick¹

1987

Dermatology

View full text Add to dashboard Cite

In addition to well-accepted indications, etretinate has a beneficial effect in a variety of other dermatoses such as the hyperkeratotic eczema of the palms and soles, prurigo nodularis, and other nonpsoriatic, sterile, pustular eruptions. Due to its influence on dermal inflammatory processes and immunomodulation of the tissue response, etretinate is effective in cutaneous lupus erythematosus, certain bullous disorders like pemphigus herpetiformis, the persistent variant of Grover’s disease, dermatitis herpetiformis, and bullous pemphigoid. Isotretinoin is reported to be effective in cutaneous sarcoidosis, disseminated granuloma annulare, systemic sclerosis and tumors of the cutaneous appendages. New synthetic retinoids have been developed. Etretin, the main metabolite of etretinate, was shown to be effective and to have a short elimination half-life of – 50 h. Arotinoid ethyl ester and arotinoid-free carboxylic acid are effective in minimal doses 500-fold lower than etretinate. Arotinoid ethyl ester was shown not to increase serum lipids. Arotinoid ethyl sulfone is the first retinoid without bone toxicity in animal experiments. Motretinide is the ethylamide of tretinoin and is reported to be effective in the local treatment of acne. Some of the new poly-aromatic retinoids appear to have sebosuppressive, antikeratinizing and/or anti-inflammatory effects via topical application.

show abstract

Section: Isotretinoinmentioning

confidence: 99%

New Indications and New Retinoids

Gollnick¹

1987

Dermatology

View full text Add to dashboard Cite

show abstract

“…66 The following therapies have been reported to be effective: photodynamic therapy, treatment with a 1450-nm diode laser, isotretinoin, bichloracetic acid, cryosurgery, electrodessication, and treatment with an argon laser, a pulsed-dye laser, and a carbon dioxide laser. [67][68][69][70][71][72][73][74][75][76][77][78][79] NSJ is a benign lesion that occurs most frequently on the scalp (59.3%) but has also been found on the face (32.6%), preauricular area (3.8%), neck (3.2%), and locations off the head and neck (1.3%). 80 It was originally described in 1895 by Jadassohn.…”

mentioning

confidence: 99%

Sebaceous lesions and their associated syndromes: Part I

Eisen¹,

Michael²

2009

Journal of the American Academy of Dermatology

127

114

View full text Add to dashboard Cite

Sebaceous neoplasms have long been a source of confusion to dermatologists and pathologists alike. Disagreements regarding nomenclature, classification, and management have been longstanding. Sebaceous lesions represent a broad spectrum of interesting entities that range from hamartomas, hyperplasias, and benign tumors to highly malignant neoplasms. This article discusses the clinical and pathologic features of sebaceous hyperplasia, nevus sebaceous of Jadassohn, sebaceous adenoma, seboacanthoma, sebaceous epithelioma, sebaceoma, mantleoma, basal cell carcinoma with sebaceous differentiation, sebomatricoma (sebomatrixoma), and sebaceous carcinoma. Controversies regarding these lesions will be explored, and any relationship with Muir-Torre syndrome will be discussed.

show abstract

“…However, the special distribution sparing the periorificial areas was not documented. Rarely, premature diffuse sebaceous hyperplasia occurs in patients with anhidrotic or hypohidrotic ectodermal dysplasia, those with Muir–Torre syndrome, and post‐transplantation patients taking oral cyclosporin A or azathioprine . Single‐lesion premature sebaceous hyperplasia (which has been postulated to be a hamartoma that originates from mature hair stem cells) is distinguished from premature diffuse sebaceous hyperplasia by its distribution and number of lesions.…”

Section: Discussionmentioning

confidence: 99%

“…Isotretinoin has antiproliferative effects on sebocytes and starts to reduce the size of sebaceous glands in 1 week, reaches a maximum effect in 3–6 weeks and induces perifollicular fibrosis after 12 weeks of therapy . The initial dose was 0.5–1 mg/kg per day for a minimum of 3 weeks and was then gradually tapered to a lower maintenance dose . High recurrence rates were noted after abrupt discontinuation .…”

Section: Discussionmentioning

confidence: 99%

Presenile diffuse familial sebaceous hyperplasia successfully treated with low‐dose isotretinoin: A report of two cases and review of the published work

Liu

Cheng

Liu

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Presenile diffuse familial sebaceous hyperplasia (PDFSH) presents as extensive yellowish papules with central umbilication on the face without involvement of periorificial regions and occurs in adolescents or young adults with a positive family history. Thirteen cases of PDFSH have been reported in the English‐language published work, 10 of which responded to oral isotretinoin from 0.5 to 1 mg/kg per day but recurrences were often observed. Herein, we report two cases of PDFSH, which were successfully managed without recurrence with prolonged low‐dose isotretinoin (0.2 mg/kg per day, a cumulative dose of 41 and 64 mg/kg, respectively). Treatment protocols among different published works were reviewed to verify the efficacy of isotretinoin.

show abstract

Premature sebaceous gland hyperplasia: Successful treatment with isotretinoin

Cited by 33 publications

References 6 publications

New Indications and New Retinoids

New Indications and New Retinoids

Sebaceous lesions and their associated syndromes: Part I

Presenile diffuse familial sebaceous hyperplasia successfully treated with low‐dose isotretinoin: A report of two cases and review of the published work

Contact Info

Product

Resources

About